Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H26N2O4 |
Molecular Weight | 310.3886 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)COC1=C(OCC(O)CNC(C)(C)C)C=CC=C1
InChI
InChIKey=UWCBNAVPISMFJZ-UHFFFAOYSA-N
InChI=1S/C16H26N2O4/c1-16(2,3)18-9-12(19)10-21-13-7-5-6-8-14(13)22-11-15(20)17-4/h5-8,12,18-19H,9-11H2,1-4H3,(H,17,20)
Molecular Formula | C16H26N2O4 |
Molecular Weight | 310.3886 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Cetamolol is a beta adrenergic antagonist with intrinsic sympathomimetic activity, patented by Imperial Chemical Industries Ltd for cardiovascular disease treatment. The average plasma half-life of cetamolol is 6.4 hours in humans and peak serum levels are reached 1 to 2 hours after drug intake; oral doses as low as 10 mg produced significant reductions in exercise-induced tachycardia 24 hours after drug administration. Cetamolol is approximately three times as potent as atenolol in blocking exercise-induced tachycardia.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2905711
15 mg/day
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:31:42 GMT 2023
by
admin
on
Sat Dec 16 16:31:42 GMT 2023
|
Record UNII |
Z0VD1633O8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29576
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3079
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
PRIMARY | |||
|
C038931
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
PRIMARY | |||
|
CHEMBL156885
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
PRIMARY | |||
|
Cetamolol
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
PRIMARY | |||
|
100000082049
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
PRIMARY | |||
|
C81659
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
PRIMARY | |||
|
m1066
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB07446MIG
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
PRIMARY | |||
|
53698
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
PRIMARY | |||
|
5144
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
PRIMARY | |||
|
DTXSID20865739
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
PRIMARY | |||
|
34919-98-7
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
PRIMARY | |||
|
Z0VD1633O8
Created by
admin on Sat Dec 16 16:31:43 GMT 2023 , Edited by admin on Sat Dec 16 16:31:43 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |